

## Decavanadate displaces inositol 1,4,5-trisphosphate (IP<sub>3</sub>) from its receptor and inhibits IP<sub>3</sub> induced Ca<sup>2+</sup> release in permeabilized pancreatic acinar cells

K.J. FÖHR<sup>1</sup>, Y. WAHL<sup>1</sup>, R. ENGLING<sup>1</sup>, T.P. KEMMER<sup>2</sup> and M. GRATZL<sup>1</sup>

<sup>1</sup>Abteilung Anatomie und Zellbiologie der Universität Ulm, Ulm, Germany

<sup>2</sup>Abteilung Innere Medizin II der Universität Ulm, Ulm, Germany

**Abstract** — Inositol 1,4,5-trisphosphate (IP<sub>3</sub>) induced Ca<sup>2+</sup> release in digitonin permeabilized rat pancreatic acinar cells is specifically inhibited by decavanadate. The Ca<sup>2+</sup> release induced with 0.18 μM IP<sub>3</sub> is half maximally inhibited with approximately 5 μM decavanadate. Complete inhibition is achieved with around 20 μM decavanadate. Removal of decavanadate from the permeabilized cells fully restores sensitivity towards IP<sub>3</sub>, indicating the reversibility of the inhibition. Oligovanadate, which inhibits ATP dependent Ca<sup>2+</sup> uptake into intracellular stores, does not influence IP<sub>3</sub> induced Ca<sup>2+</sup> release. In order to reveal the mechanism underlying the effects of the different vanadate species, binding of IP<sub>3</sub> to the same cellular preparations was investigated. We found that binding of IP<sub>3</sub> to a high affinity receptor site (K<sub>d</sub> approx. 1.2 nM) could be abolished by decavanadate but not by oligovanadate. With 0.5 μM decavanadate, IP<sub>3</sub> binding was half maximally inhibited. A similar potency of decavanadate was also found with adrenal cortex microsomes which bind IP<sub>3</sub> with the same affinity (K<sub>d</sub> approx. 1.4 nM) as permeabilized pancreatic acinar cells. Labelled IP<sub>3</sub> was displaced from these subcellular membranes with similar kinetics by unlabelled IP<sub>3</sub> and decavanadate. The data suggest that the inhibitory action of decavanadate on IP<sub>3</sub> induced Ca<sup>2+</sup> release is a consequence of its effect on binding of IP<sub>3</sub> to its receptor.

Intracellular inositol 1,4,5-trisphosphate (IP<sub>3</sub>), formed at the plasma membrane by the hydrolysis of phosphatidylinositol-4,5-bisphosphate, causes the release of Ca<sup>2+</sup> from intracellular stores [1]. The

*Abbreviations used* : EGTA, ethylene-glycol-bis (2-aminoethylether)-N,N,N',N'-tetraacetic acid; EDTA, ethylenediaminetetraacetic acid; PEG, polyethylene glycol; IP<sub>3</sub>, inositol 1,4,5-trisphosphate; MOPS, morpholino-propane sulfonic acid; HEPES, N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid; Tris, tris(hydroxymethyl)-aminomethane

latter was shown for the first time with permeabilized rat pancreatic acinar cells [2] and was subsequently confirmed by innumerable investigations in a variety of cells. Our knowledge concerning the mechanism of the IP<sub>3</sub> induced Ca<sup>2+</sup> release is still limited although the primary structure of the IP<sub>3</sub> receptor has been determined [3, 4]. A useful tool to characterize the IP<sub>3</sub> receptor is heparin. It inhibits binding of IP<sub>3</sub> to its receptor [5-7] and IP<sub>3</sub> induced Ca<sup>2+</sup> release [8-10]. The isolation of the IP<sub>3</sub> receptor on heparin agarose and

its incorporation into lipid vesicles led to the conclusion that the IP<sub>3</sub> receptor itself forms the Ca<sup>2+</sup> channel [11].

In a previous report we introduced decavanadate as a specific inhibitor of the IP<sub>3</sub> induced Ca<sup>2+</sup> release of rat insulinoma and rat pheochromocytoma cells [12]. In the present study we focused our interest on rat pancreatic acinar cells, which are similar to permeabilized chromaffin cells [13], but in contrast to the above mentioned tumor cells require GTP during the repetitive IP<sub>3</sub> induced Ca<sup>2+</sup> release [14]. The investigation of decavanadate effects on Ca<sup>2+</sup> release in these different cell types is of interest, since heparin reportedly only inhibits the IP<sub>3</sub> induced Ca<sup>2+</sup> release, whereas the GTP-activated Ca<sup>2+</sup> translocation is unaffected [9]. Here we show that decavanadate completely inhibits IP<sub>3</sub> induced and GTP modulated Ca<sup>2+</sup> release from permeabilized pancreatic acinar cells, indicating that decavanadate influences a step in the Ca<sup>2+</sup> release mechanism common to several different cell types. Furthermore, we found that decavanadate inhibits binding of IP<sub>3</sub> to its receptor in permeabilized pancreatic acinar cells as well as in isolated adrenal cortex microsomes. By contrast, the related compound oligovanadate, which inhibits ATP dependent Ca<sup>2+</sup> uptake into intracellular stores, has no effect on IP<sub>3</sub> induced Ca<sup>2+</sup> release or binding of IP<sub>3</sub> to its receptor protein. Thus, oligovanadate and decavanadate are highly selective substances which specifically inhibit either Ca<sup>2+</sup> uptake or Ca<sup>2+</sup> release by the IP<sub>3</sub> sensitive intracellular Ca<sup>2+</sup> store.

## Materials and Methods

### Chemicals

Collagenase was purchased from Serva (Heidelberg, Germany). Soybean trypsin inhibitor and IP<sub>3</sub> were from Boehringer (Mannheim, Germany). [<sup>3</sup>H]-IP<sub>3</sub> (specific activity 17 Ci/mmol) was from New England Nuclear (UK). Ca<sup>2+</sup> selective membranes containing the neutral carrier ETH 129 were prepared as described [15]. KCl suprapur was from Merck (Darmstadt, Germany), and Azur A was from Fluka (Neu-Ulm, Germany). All other chemicals were of analytical grade.

### Isolation of exocrine pancreatic acinar cells

Pancreatic acinar cells were prepared as described previously [16] with modifications according to [17]. Briefly, pancreatic tissue from four male Wistar rats (200–250 g) fasted overnight was chopped with scissors and incubated in a standard medium containing (in mM): 145 NaCl, 4.7 KCl, 1.2 KH<sub>2</sub>PO<sub>4</sub>, 1.2 MgCl<sub>2</sub>, 2 CaCl<sub>2</sub>, 10 HEPES (pH 7.4), 15 glucose, 0.2 % BSA, 0.01 % soybean trypsin inhibitor plus collagenase (150 U/ml) for 15 min at 37°C. In order to get single cells a washing step in the above Ca<sup>2+</sup> free medium (CaCl<sub>2</sub> replaced by 1 mM EDTA, without collagenase) was interposed, followed by a further digestion by collagenase (210 U/ml) for 50–60 min at 37°C. During cell isolation the medium was continuously gassed with oxygen in a water bath at 37°C. Acinar cells were then mechanically dissociated by sequential passages through polypropylene pipettes of decreasing tip diameter (about 5, 3 and 2 mm) after 40 min of the second collagenase digestion step. The cell suspension was diluted with standard medium, and centrifuged for 5 min at 85 g. The pellet was resuspended in standard buffer and filtered through a double layer of medical gauze, placed over 30 ml of standard medium containing 8% albumin. The suspension was centrifuged again. Finally, the pellet was washed three times in the standard medium as described above.

### Permeabilization of pancreatic acinar cells with digitonin

The resultant cell suspension was washed three times by centrifugation (80 *g*<sub>av</sub>, 3 min) in medium A containing in mM: 150 KCl, 5 NaN<sub>3</sub>, 1 EGTA and 20 MOPS (pH 7.2). Permeabilization was carried out on ice with 10 μM digitonin which was added to medium A from a stock where it was dissolved in dimethyl sulfoxide (DMSO). The final concentration of DMSO was less than 0.1 %. Permeabilization was controlled by counting the Azur A (0.25 % in medium A) stained cells. Following permeabilization, the cells were washed three times in medium B (medium A without EGTA) by centrifugation (400 *g*<sub>av</sub>, 3 min).

### *Measurement of free Ca<sup>2+</sup> concentration*

Ca<sup>2+</sup> specific mini-electrodes were prepared as described [15]. Ca<sup>2+</sup> specific electrodes were calibrated using the same ionic background for calibration as used for Ca<sup>2+</sup> measurements. The poly (vinyl chloride) membrane of the electrode contained the recently developed neutral carrier ETH 129, which allows reliable measurements of Ca<sup>2+</sup> down to the nanomolar range [18, 19]. Experiments were carried out at room temperature and pH 7.2 in 400 µl of medium B containing 3–6 × 10<sup>6</sup> cells. 10<sup>7</sup> cells correspond to 1.5 mg of cell protein. During Ca<sup>2+</sup> uptake experiments, medium B contained 1 mM Mg<sup>2+</sup> and 20 µM ATP, and during Ca<sup>2+</sup> release experiments, medium B contained 2 mM Mg<sup>2+</sup> and 2 mM ATP [14]. The absolute amount of Ca<sup>2+</sup> fluxes was calibrated in each experiment by the addition of suitable dilutions of a neutral Ca<sup>2+</sup> standard (Orion, Lorch, Germany). Guanine nucleotides were present during Ca<sup>2+</sup> measurements as indicated in the figure captions.

### *Preparation of bovine adrenal cortex microsomes*

Bovine adrenal glands were obtained from the local slaughter house. Cortex microsomes were essentially prepared as previously described [20]. Briefly, the isolated cortex of adrenal glands was homogenized in 20 mM NaHCO<sub>3</sub>, 1 mM DTT, pH 8.0 in a Teflon-to-glass homogenizer with 5 strokes at 800 revs/min. The homogenate was centrifuged at 5000 g, 4°C for 15 min and rehomogenized. From the pooled supernatants, the microsomes were spun down at 100 000 g, 4°C for 30 min and the pellet was washed again. The final pellet was resuspended in the homogenisation buffer described above at a protein concentration of 5 mg/ml and stored at -20°C.

### *Determination of IP<sub>3</sub> binding*

IP<sub>3</sub> binding assays were carried out according to the method of Challis [20]. Briefly, digitonin permeabilized cells were washed three times by centrifugation (450 g<sub>av</sub>, 3 min) in a medium containing in mM: 100 Tris, 20 MOPS, 240 sucrose, 2 EDTA, 2 EGTA, 2% PEG and a final pH of 8.0. Each assay

tube contained 0.9 nM [<sup>3</sup>H]-IP<sub>3</sub> (6000 cpm/assay) and unlabelled IP<sub>3</sub> as indicated in the figure captions. The assays were carried out at 4°C with 0.5 mg protein of permeabilized cells or 0.4 mg protein of adrenal cortex microsomes in a final volume of 400 µl. During the incubation (15 min), samples were vortex-mixed every 3 min. Thereafter, bound and free IP<sub>3</sub> were separated by centrifugation (10 000 g, 30 s) in an Ole Dich microcentrifuge 154. The supernatant was aspirated and the pellet dissolved in 5 ml scintillant. Nonspecific binding (NSB) was defined as binding of [<sup>3</sup>H]-IP<sub>3</sub> in the presence of 2 µM IP<sub>3</sub> (final).

### *Preparation of defined vanadate species*

Oligovanadate and decavanadate were prepared as described [12] with the following modifications. In order to avoid high salt concentrations (due to dissolving of vanadate in 1 M KOH), crystals of orthovanadate were dissolved in medium B as a stock of 50 mM. For the preparation of decavanadate, the pH was adjusted to 3.75 and for the preparation of oligovanadate the pH was adjusted to 7.2 with HCl. Finally the preparations were boiled for 5 min. Oligovanadate concentrations refer to the monomeric form.

## **Results and Discussion**

### *Decavanadate inhibits IP<sub>3</sub> induced Ca<sup>2+</sup> release*

In the presence of 5 mM sodium azide (NaN<sub>3</sub>) and 2 mM Mg<sup>2+</sup>/ATP, permeabilized exocrine pancreatic acinar cells sequester Ca<sup>2+</sup> mainly within non-mitochondrial intracellular Ca<sup>2+</sup> stores [14]. The application of submicromolar concentrations of inositol 1,4,5-trisphosphate results in a transient Ca<sup>2+</sup> release which is followed by the immediate reuptake of released Ca<sup>2+</sup>. In the presence of 20 µM GTP, a constant Ca<sup>2+</sup> release occurs during the repeated application of the same amount of IP<sub>3</sub> from permeabilized pancreatic acinar cells (Fig. 1; see also [14]). Streptolysin O permeabilized chromaffin cells exhibit the same behaviour [13]. We found that increasing concentrations of decavanadate dose dependently inhibited the Ca<sup>2+</sup> transients induced by




Fig. 1  $\text{Ca}^{2+}$  release by  $\text{IP}_3$  pulses in the presence of GTP from permeabilized pancreatic acinar cells.

$\text{Ca}^{2+}$  fluxes of digitonin ( $10 \mu\text{M}$ ) permeabilized pancreatic acinar cells ( $5.9 \times 10^6$  cells) were recorded with a  $\text{Ca}^{2+}$  selective electrode. The presence of  $20 \mu\text{M}$  GTP in medium B (containing in mM:  $2 \text{Mg}^{2+}/\text{ATP}$ ,  $5 \text{NaN}_3$ ,  $150 \text{KCl}$ ,  $20 \text{MOPS}$  pH 7.2) assured constant  $\text{Ca}^{2+}$  release during the repeated application of  $0.25 \mu\text{M}$   $\text{IP}_3$

$\text{IP}_3$  (Fig. 2a). With  $0.18 \mu\text{M}$   $\text{IP}_3$ , half maximal inhibition occurred with around  $5 \mu\text{M}$  decavanadate which was complete with  $20 \mu\text{M}$  decavanadate (Fig. 2b). A similar half maximal effective decavanadate concentration was reported for rat insulinoma and rat pheochromocytoma cells [12].

The inhibition of the  $\text{IP}_3$  induced  $\text{Ca}^{2+}$  release by decavanadate can not be explained by a decreased  $\text{Ca}^{2+}$  uptake, since decavanadate, unlike oligovanadate, did not influence the ATP driven  $\text{Ca}^{2+}$  uptake (Fig. 3). On the other hand, oligovanadate did not affect the  $\text{IP}_3$  induced  $\text{Ca}^{2+}$  release (not shown). Thus decavanadate specifically affects the  $\text{IP}_3$  induced  $\text{Ca}^{2+}$  release, while the action of oligovanadate is restricted to the  $\text{Ca}^{2+}$  uptake system. Furthermore, removing decavanadate by centrifugation and repeating the same experiment after resuspending the cells resulted in a full response to  $\text{IP}_3$  (not shown). This indicates that the inhibition of the  $\text{IP}_3$  induced  $\text{Ca}^{2+}$  release by decavanadate is reversible.

#### Decavanadate displaces $\text{IP}_3$ from its receptor

The structural similarity of decavanadate ( $\text{V}_{10}\text{O}_{28}^{6-}$ ) [21, 22] with  $\text{IP}_3$  suggested that they might interact with the same sites. Therefore, we investigated the effects of different vanadate species on binding of  $\text{IP}_3$  to its receptor. These studies were also

performed with permeabilized cells, i.e. with cellular preparations identical to that used for the investigation of  $\text{Ca}^{2+}$  fluxes. A 50% displacement of the labelled ligand ( $0.9 \text{nM}$  [ $^3\text{H}$ ]- $\text{IP}_3$ ) was attained with  $1.2 \text{nM}$  of unlabelled ligand (Fig. 4a). Scatchard-analysis of these data revealed a binding capacity of  $140 \text{fmol}$   $\text{IP}_3/\text{mg}$  cell protein (Fig. 4b). The binding of [ $^3\text{H}$ ]- $\text{IP}_3$  by permeabilized pancreatic acinar cells was potently inhibited by decavanadate





Fig. 2 Decavanadate inhibits  $\text{IP}_3$  induced  $\text{Ca}^{2+}$  release.

(a)  $\text{Ca}^{2+}$  transients were recorded under identical conditions as described in Figure 1. Increasing amounts of decavanadate were added stepwise to the permeabilized cells immediately before stimulation with  $0.18 \mu\text{M}$   $\text{IP}_3$ . The addition of decavanadate did not change medium free  $\text{Ca}^{2+}$  concentration by itself, but it inhibited the subsequent  $\text{Ca}^{2+}$  release induced by  $\text{IP}_3$

(b) Summary of 5 independent experiments as shown in Figure 2a (means  $\pm$  SD). 100% corresponds to the  $\text{Ca}^{2+}$  release in the absence of decavanadate




**Fig. 3** Effect of oligo- and decavanadate on ATP driven Ca<sup>2+</sup> uptake. Effects on Ca<sup>2+</sup> uptake were estimated by inducing transient Ca<sup>2+</sup> uptake with low concentrations of ATP (20 μM; see also [12, 13]). 100% corresponds to a Ca<sup>2+</sup> uptake of 2.5 to 3.8 nmol Ca<sup>2+</sup>/10<sup>7</sup> cells (n = 5) which was carried out in the absence of vanadate. Oligo- or decavanadate were added in increasing amounts immediately prior to the additions of ATP. Vanadate concentrations refer to the monomeric form

(half maximal effective concentration of 0.5 μM), whereas oligovanadate was completely ineffective, even when tested at concentrations of 500 μM (Fig. 5). Thus, it can be concluded that the inhibition of the IP<sub>3</sub> induced Ca<sup>2+</sup> release by decavanadate in pancreatic acinar cells is a consequence of the displacement of IP<sub>3</sub> from its binding site.


In order to establish the effects of decavanadate on IP<sub>3</sub> binding, we also performed IP<sub>3</sub> binding studies with isolated adrenal cortex microsomes, which are rich in IP<sub>3</sub> receptors and bind IP<sub>3</sub> with the same affinity as pancreatic acinar cells. We found a K<sub>d</sub> of 1.4 nM and 2.3 pmol binding sites per mg protein. For adrenal cortical microsomes, half maximal displacement occurred around 0.5 μM decavanadate, whereas 500 μM oligovanadate was completely ineffective in displacing IP<sub>3</sub> (Fig. 6). Both 2 μM IP<sub>3</sub> and 25 μM decavanadate resulted in a very similar and rapid dissociation of labelled IP<sub>3</sub> from the receptor (Fig. 7).

The dissociation constant (1.2 nM) for the binding of IP<sub>3</sub> to its receptor in rat pancreatic acinar cells reported here is in the same order of magnitude as reported for permeabilized rat liver cells [23],




**Fig. 4** Binding of IP<sub>3</sub> to permeabilized pancreatic acinar cells. (a) Digitonin permeabilized cells (500 μg cell protein) were incubated with 0.9 nM [<sup>3</sup>H]-IP<sub>3</sub> and increasing concentrations of unlabelled IP<sub>3</sub>. Specific binding is expressed as the percentage of [<sup>3</sup>H]-IP<sub>3</sub> bound in the presence of various concentrations of unlabelled IP<sub>3</sub> (B) and in the absence of unlabelled IP<sub>3</sub> (Bo), with each value corrected for nonspecific binding (NSB). Nonspecific binding was defined in the presence of 2 μM unlabelled IP<sub>3</sub> and was typically 30% of total binding. The graph shows one out of three similar experiments carried out in triplicate (b) Scatchard plot of a single representative experiment with triplicate determinations of each point. The data were fitted by linear regression. In three experiments a K<sub>d</sub> = 1.2 nM and B<sub>max</sub> = 140 fmol/mg of protein were estimated


whereas submicromolar dissociation constants have been reported for permeabilized guinea pig hepatocytes and rabbit neutrophils [24]. Similarly the dissociation constant (1.4 nM) for the binding of



**Fig. 5** Decavanadate inhibits binding of IP<sub>3</sub> to its receptor in permeabilized pancreatic acinar cells. Permeabilized cells were incubated with 0.9 nM [<sup>3</sup>H]-IP<sub>3</sub> and different concentrations of decavanadate (DV) and oligovanadate (OV). Nonspecific binding (NSB) was defined as binding in the presence of 2 μM unlabelled IP<sub>3</sub>. 100% corresponds to the binding of [<sup>3</sup>H]-IP<sub>3</sub> in the absence of vanadate species and in the absence of unlabelled IP<sub>3</sub>. The figure shows the mean (± SD) of 3 independent experiments carried out in triplicate. Oligovanadate refers to the monomeric form



**Fig. 6** Decavanadate inhibits binding of IP<sub>3</sub> to its receptor from adrenal cortex microsomes. Isolated adrenal cortex microsomes (0.4 mg protein) were incubated in a final volume of 400 μl with 0.9 nM [<sup>3</sup>H]-IP<sub>3</sub> and different concentrations of decavanadate (Deca) and oligovanadate (Oligo). For experimental details, see Materials and Methods. The figure shows the mean (± SD) of 3 independent experiments carried out in triplicate. Oligovanadate refers to the monomeric form



**Fig. 7** Displacement of [<sup>3</sup>H]-IP<sub>3</sub> from adrenal cortex microsomes by unlabelled IP<sub>3</sub> and decavanadate. The time dependent association of [<sup>3</sup>H]-IP<sub>3</sub> (0.9 nM) with the receptor of adrenal cortex microsomes (circles) was determined. After 15 min, either 2 μM unlabelled IP<sub>3</sub> (squares) or 25 μM decavanadate (triangles) were added as indicated by the arrow. 100% corresponds to the binding of [<sup>3</sup>H]-IP<sub>3</sub> as determined after 30 min. The data in this figure are representative of 1 out of 3 independent experiments

IP<sub>3</sub> to isolated adrenal cortex microsomes is in accordance with the K<sub>d</sub> value reported for isolated microsomes from different cell types [20, 25, 26].

Although the estimated IP<sub>3</sub> concentration which causes half maximal Ca<sup>2+</sup> release (approx. 0.2 μM at 0.2 μM free Ca<sup>2+</sup>; see also [13]) is in accordance with the observation of other authors (see [1, 27, 13]) it contrasts with the dissociation constant for IP<sub>3</sub> (1.2 nM) found within the same cellular preparation. A similar discrepancy, when comparing displacement of IP<sub>3</sub> from its receptor with its potency in Ca<sup>2+</sup> mobilization, was also observed with microsomes from the adrenal cortex [26, 28]. In this context, the higher amounts of decavanadate (5 μM) required for a half maximal inhibition of the IP<sub>3</sub> induced Ca<sup>2+</sup> release compared to the inhibition of IP<sub>3</sub> binding (0.5 μM decavanadate) are not unexpected. A similar behaviour was also reported for heparin which inhibits binding of IP<sub>3</sub> to its receptor protein and IP<sub>3</sub> induced Ca<sup>2+</sup> release, as does decavanadate [10]. Certainly some of these differences may be explained by the different experimental conditions used for the different assays. Besides the difference in ionic strength and pH, it should be noted that the Ca<sup>2+</sup> release experiments (to keep Ca<sup>2+</sup> in the store) must be

carried out in the presence of millimolar concentrations of Mg<sup>2+</sup> and ATP, while displacement assays are carried out in their absence. Both Mg<sup>2+</sup> and ATP affect IP<sub>3</sub> metabolism [29, 30] and binding of IP<sub>3</sub> [7, 20, 23]. Under our experimental conditions, 1 mM ATP reduced IP<sub>3</sub> binding to about 10% of that measured in the absence of ATP. Identical values for IP<sub>3</sub> binding and Ca<sup>2+</sup> releasing potency have recently been reported using identical conditions for both assays [23].

## Conclusions

In conclusion, decavanadate appears to be the most useful inhibitor of IP<sub>3</sub> induced Ca<sup>2+</sup> release and inhibitor of IP<sub>3</sub> binding to its receptor protein. Compared to decavanadate, rather high concentrations of other polyanions (patent blue, cibacron blue) have been reported to displace IP<sub>3</sub> from its receptor [31], but the effects of these substances on subsequent steps leading to IP<sub>3</sub> induced Ca<sup>2+</sup> release have not been elucidated. Additionally, decavanadate-mediated inhibition provides a sensitive marker to assess IP<sub>3</sub> binding sites in permeabilized cells, microsome fractions and IP<sub>3</sub> receptor preparations. Finally, the small molecular size and well defined chemical structure [21, 22] of decavanadate furnish important advantages over heparin for further characterization of the IP<sub>3</sub> binding site on its receptor.

## Acknowledgements

This work was supported by the Deutsche Forschungsgemeinschaft (Gr 681) and a starting grant from the University of Ulm. The expert technical assistance of Mrs Claudia Längle and the helpful advice during the preparation of the English version of the manuscript by Mrs Sara Watkins are gratefully acknowledged.

## References

- Berridge MJ. (1987) Inositol trisphosphate and diacylglycerol: Two interacting second messengers. *Annu. Rev. Biochem.*, 56, 159-193.
- Streb H. Irvine RF. Berridge MJ. Schulz I. (1983) Release of calcium from a nonmitochondrial intracellular store in pancreatic acinar cells by inositol 1,4,5-trisphosphate. *Nature*, 306, 67-69.
- Furuichi T. Yoshikawa S. Miyawaki A. Wada K. Maeda N. Mikoshiba K. (1989) Primary structure and functional expression of the inositol 1,4,5-trisphosphate-binding protein P400. *Nature*, 342, 32-38.
- Mignery GA. Newton CL. Archer III BT. Südhof TC. (1990) Structure and expression of the rat inositol 1,4,5-trisphosphate receptor. *J. Biol. Chem.*, 265, 12679-12685.
- Worley PF. Baraban JM. Supattapone S. Wilson VS. Snyder SH. (1987) Characterization of inositol trisphosphate receptor binding in brain. *J. Biol. Chem.*, 262, 12132-12136.
- Supattapone S. Worley PF. Baraban JM. Snyder SH. (1988) Solubilization, purification, and characterization of an inositol trisphosphate receptor. *J. Biol. Chem.*, 263, 1530-1534.
- Vamey MA. Rivera J. Lopez Bernal A. Watson SP. (1990) Are there subtypes of the inositol 1,4,5-trisphosphate receptor? *Biochem. J.*, 269, 211-216.
- Cullen PJ. Comerford JG. Dawson AP. (1988) Heparin inhibits the inositol 1,4,5-trisphosphate-induced Ca<sup>2+</sup> release from rat liver microsomes. *FEBS Lett.*, 228, 57-59.
- Ghosh TK. Eis PS. Mullaney JM. Ebert CL. Gill DL. (1988) Competitive, reversible, and potent antagonism of inositol 1,4,5-trisphosphate-activated calcium release by heparin. *J. Biol. Chem.*, 263, 11075-11079.
- Ely JA. Hunyady L. Baukal AJ. Catt KJ. (1990) Inositol 1,3,4,5-tetrakisphosphate stimulates calcium release from bovine adrenal microsomes by a mechanism independent of the inositol 1,4,5-trisphosphate receptor. *Biochem. J.*, 268, 333-338.
- Ferris CD. Haganir RL. Supattapone S. Snyder SH. (1989) Purified inositol 1,4,5-trisphosphate receptor mediates calcium flux in reconstituted lipid vesicles. *Nature*, 342, 87-89.
- Föhr KJ. Scott J. Ahnert-Hilger G. Gratzl M. (1989) Characterization of the inositol 1,4,5-trisphosphate-induced calcium release from permeabilized endocrine cells and its inhibition by decavanadate and *p*-hydroxymercuribenzoate. *Biochem. J.*, 262, 83-89.
- Föhr KJ. Ahnert-Hilger G. Stecher B. Scott J. Gratzl M. (1991) GTP and calcium modulate the inositol 1,4,5-trisphosphate dependent calcium release in streptolysin O permeabilized bovine adrenal chromaffin cells. *J. Neurochem.*, 56, 665-670.
- Engling R. Föhr KJ. Kemmer TP. Gratzl M. (1991) Effect of GTP and calcium on inositol 1,4,5-trisphosphate induced calcium release from permeabilized rat exocrine pancreatic acinar cells. *Cell Calcium*, 12, 1-9.
- Föhr KJ. Warchol W. Gratzl M. (1990) Calculation and control of free divalent cations in solutions used for membrane fusion studies. *Meth. Enzymol.*, In press.
- Amsterdam A. Jamieson JD. (1972) Structural and functional characterization of isolates from pancreatic exocrine cells. *Proc. Natl. Acad. Sci. USA*, 69, 3028-3032.
- Streb H. Schulz I. (1983) Regulation of cytosolic free calcium concentration in acinar cells of rat pancreas. *Am. J. Physiol.*, 245, G347-G357.

18. Schefer U. Ammann D. Pretsch E. Oesch U. Simon W. (1986) Neutral carrier based  $\text{Ca}^{2+}$ -selective electrode with detection limit in the sub-nanomolar range. *Anal. Chem.*, 58, 2282-2285.
19. Ammann D. Bühler T. Schefer U. Müller M. Simon W. (1987) Intracellular neutral carrier-based calcium microelectrode with subnanomolar detection limit. *Pflügers Arch.*, 409, 223-228.
20. Challis RAJ. Chilvers ER. Willcocks AL. Nahorski SR. (1990) Heterogeneity of [ $^3\text{H}$ ]-inositol 1,4,5-trisphosphate binding sites in adrenal-cortical membranes. *Biochem. J.*, 265, 421-427.
21. Evans Jr HT. (1966) The molecular structure of the isopoly complex ion, decavanadate ( $\text{V}_{10}\text{O}_{28}^{6-}$ ). *Inorg. Chem.* 5, 967-977.
22. Swallow AG. Ahmed FR. Barnes WH. (1966) The crystal structure of pascoite,  $\text{Ca}_3\text{V}_{10}\text{O}_{28}\cdot 17\text{H}_2\text{O}$ . *Acta Cryst.* 21, 397-405.
23. Numm DL. Taylor CW. (1990) Liver inositol 1,4,5-trisphosphate-binding sites are the  $\text{Ca}^{2+}$ -mobilizing receptors. *Biochem. J.*, 270, 227-232.
24. Spät A. Bradford PG. McKinney JS. Rubin RP. Putney Jr JW. (1986) A saturable receptor for  $^{32}\text{P}$ -inositol 1,4,5-trisphosphate in hepatocytes and neutrophils. *Nature*, 319, 514-516.
25. Baukal AJ. Guillemette Rubin R. Spät A. Catt KJ. (1985) Binding sites for inositol trisphosphate in the bovine adrenal cortex. *Biochem. Biophys. Res. Commun.*, 133, 532-538.
26. Guillemette G. Balla T. Baukal AJ. Spät A. Catt KJ. (1987) Intracellular receptors for inositol 1,4,5-trisphosphate in angiotensin II target tissues. *J. Biol. Chem.*, 262, 1010-1015.
27. Berridge MJ. Irvine RF. (1984) Inositol trisphosphate, a novel second messenger in cellular signal transduction. *Nature*, 312, 315-321.
28. Rossier MF. Capponi AM. Vailotton MB. (1989) The inositol 1,4,5-trisphosphate-binding site in adrenal cortical cells is distinct from the endoplasmic reticulum. *J. Biol. Chem.*, 264, 14078-14084.
29. Downes CP. Mussat MC. Michell RH. (1982) The inositol trisphosphate phosphomonoesterase of the human erythrocyte membrane. *Biochem. J.*, 203, 169-177.
30. Irvine RF. Moor RM. Pollock WK. Smith PM. Wreggett KA. (1988) Inositol phosphates: proliferation metabolism and function. *Phil. Trans. R. Soc. Lond. [B]*, 320, 281-298.
31. Bootman MD. Pay GF. Rick CE. Tones MA. (1990) Two sulphonated dye compounds which compete for inositol 1,4,5-trisphosphate binding to rat liver microsomes: effects on 5'-phosphatase activity. *Biochem. Biophys. Res. Commun.*, 166, 1334-1339.

Please send reprint requests to : Prof. Dr M. Gratzl, Abteilung Anatomie und Zellbiologie der Universität Ulm, Postfach 4066, D-7900 Ulm, Germany

Received : 29 May 1991

Revised : 16 August 1991

Accepted : 16 August 1991